Meanwhile, Smad7 is known as an inhibitory protein of transforming growth factor-beta (TGF-β) signaling and is negatively associated with the Akt/HO-1 survival pathway in cisplatin-administered A549 cells [65], suggesting that Smad7 targeting could be a promising strategy against drug resistance in cancer treatment through HO-1 regulation. The gene discussed is SMAD7; the disease is cancer.